All blog posts
Showing 12 out of 92 results
14 июля 2026
The EU Commission's new draft merger guidelines - key takeaways for pharma companies
16 июня 2026
2026 sees China's biotech scene continuing its ascent – but could US developments mean clouds on the horizon?
27 апреля 2026
The EU Pharma Package is finally here – here's the settled position on key areas
12 марта 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
15 декабря 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
09 декабря 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
15 октября 2025
Venture investment in life sciences – Activity update & outlook (US & Europe)
24 сентября 2025
Biopharma M&A activity – strategics continue to lead the way
28 августа 2025
The Thursday Investment Club: The case for later living
18 августа 2025
Pharma remains an enforcement focus in China – SAMR orders unwinding of a completed pharma deal
31 июля 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
22 июля 2025
Overview of EU regulatory and competition law in the Pharma sector
Showing 12 out of 92 results
View moreKey contacts
Laura Orlando
Managing Partner, Milan Office, Milan
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London